These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
623 related articles for article (PubMed ID: 8547862)
1. A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumors receiving high-dose combination chemotherapy. Sosman JA; Stiff PJ; Bayer RA; Peliska J; Peace DJ; Loutfi S; Stock W; Oldenburg D; Unverzagt K; Bender J Bone Marrow Transplant; 1995 Nov; 16(5):655-61. PubMed ID: 8547862 [TBL] [Abstract][Full Text] [Related]
2. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation. Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338 [TBL] [Abstract][Full Text] [Related]
3. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation. Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941 [TBL] [Abstract][Full Text] [Related]
4. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation. Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240 [TBL] [Abstract][Full Text] [Related]
5. Use of continuous infusion granulocyte-macrophage colony-stimulating factor alone or followed by granulocyte colony-stimulating factor to enhance engraftment following high-dose chemotherapy and autologous bone marrow transplantation for lymphoid malignancies. Vose JM; Bierman PJ; Ruby E; Reed EC; Bishop MR; Tarantolo S; Kessinger A; Armitage JO Bone Marrow Transplant; 1996 Jun; 17(6):951-6. PubMed ID: 8807099 [TBL] [Abstract][Full Text] [Related]
6. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163 [TBL] [Abstract][Full Text] [Related]
7. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial. Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281 [TBL] [Abstract][Full Text] [Related]
8. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial. Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838 [TBL] [Abstract][Full Text] [Related]
9. In vivo effects of GM-CSF and IL-3 on hematopoietic cell recovery in bone marrow and blood after autologous transplantation with mafosfamide-purged marrow in lymphoid malignancies. Albin N; Douay L; Fouillard L; Laporte JP; Isnard F; Lesage S; Ozsahin H; Bardinet D; Najman A; Gorin NC Bone Marrow Transplant; 1994 Aug; 14(2):253-9. PubMed ID: 7994241 [TBL] [Abstract][Full Text] [Related]
10. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574 [TBL] [Abstract][Full Text] [Related]
11. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: a retrospective analysis. Peters BG; Adkins DR; Harrison BR; Velasquez WS; Dunphy FR; Petruska PJ; Bowers CE; Niemeyer R; McIntyre W; Vrahnos D; Auberry SE; Spitzer G Bone Marrow Transplant; 1996 Jul; 18(1):93-102. PubMed ID: 8832001 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of high-dose melphalan, high-dose etoposide and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Lazarus HM; Gray R; Ciobanu N; Winter J; Weiner RS Bone Marrow Transplant; 1994 Sep; 14(3):443-8. PubMed ID: 7994270 [TBL] [Abstract][Full Text] [Related]
13. [Favorable effect of hematopoietic stem cells isolated from blood on hematologic recovery following high-dosage chemotherapy]. Richel DJ; Baars JW; Wijngaarden MJ; van der Schoot CE; Vlasveld LT; Rodenhuis S Ned Tijdschr Geneeskd; 1993 Jan; 137(5):245-50. PubMed ID: 7679478 [TBL] [Abstract][Full Text] [Related]
14. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. D'Hondt V; Guillaume T; Humblet Y; Doyen C; Chatelain B; Feyens AM; Staquet P; Osselaer JC; Müll B; Symann M Bone Marrow Transplant; 1994 Mar; 13(3):261-4. PubMed ID: 7515299 [TBL] [Abstract][Full Text] [Related]
15. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
16. Comparison of G-CSF with GM-CSF for mobilizing peripheral blood progenitor cells and for enhancing marrow recovery after autologous bone marrow transplant. Bolwell BJ; Goormastic M; Yanssens T; Dannley R; Baucco P; Fishleder A Bone Marrow Transplant; 1994 Dec; 14(6):913-8. PubMed ID: 7536072 [TBL] [Abstract][Full Text] [Related]
17. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease. de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878 [TBL] [Abstract][Full Text] [Related]
18. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation. Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310 [TBL] [Abstract][Full Text] [Related]
19. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells. Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688 [TBL] [Abstract][Full Text] [Related]
20. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]